rs28940279

A SNP in the ASPA gene on chromosome 17. Its most notable genotype is C;C: Canavan disease (predicted)

Gene
ASPA
Location
Chr 173,499,000 (GRCh38)
Highest magnitude
8.0Very important
Tested on
23andMe, AncestryDNA

Genotypes

As shown in 23andMe and AncestryDNA files.

  1. A;AGoodcommon in clinvarTypical · 0.0
  2. A;CBadCarrier of a Canavan disease mutationImportant · 3.0
  3. C;CMost notableBadCanavan disease (predicted)Very important · 8.0

On SNPedia: (A;A), (A;C), (C;C). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.

Conditions, medicines and genes

Notes

From SNPedia

Show notes, about 300 words

rs28940279, also known as c.854A>C, E285A or p.Glu285Ala, is a SNP in the ASPA gene. rs28940279 is one of several known causal SNPs of Canavan disease. Canavan disease is a degenerative disease of the nervous system. It is a childhood onset disease which begins in early infancy. It is characterized by disordered muscular behavior (e.g., hypotonia, hyperextension) and neurological symptoms, such as blindness, developmental and cognitive delays. The neurological findings appear to be due to demyelination and leukodystrophy. Histology indicates the presence of spongy degeneration; cytology confirms astrocytic swelling of normal neurons and abnormality of astrocyte mitochondria. Ultimately, sufferers become extremely ill and die on average at 18 months of age. rs28940279 is a SNP in the aspartoacylase ASPA gene. The A-C transversion results in a substitution of alanine, a hydrophobic small-chain amino acid, for a glutamate (which is both large and charged). This substitution, E285A, is at a residue predicted to be part of the catalytic domain of aspartocyclase. This missense mutation is predicted to have drastic effects on the catalytic domain because of the vast difference between the amino acids. In particular, this substitution is common in Ashkenazi Jews, with carrier frequency approximately 1 in 60 individuals. This suggests that some degree of founder effect is responsible for its prevalence within the Ashkenazi Jewish population. In particular, one study suspects that the mutation originated in the Vilna area, in Poland or Lithuania depending on the political timeperiod of origin. This suggests that it is a newer variant than others found in the more broad European population.

A;C

Unaffected in absence of a second ASPA gene mutation.

C;C

see discussion at Canavan disease and links via the main SNP page

Source and license

Adapted from rs28940279 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.

SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.